The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 10, 2018
Filed:
Dec. 05, 2016
Applicant:
Research Development Foundation, Carson City, NV (US);
Inventors:
J. Timothy Stout, Houston, TX (US);
Trevor J. McFarland, Portland, OR (US);
Binoy Appukuttan, Adelaide, AU;
Assignee:
Research Development Foundation, Carson City, NV (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/11 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); A61K 45/06 (2006.01); C07K 14/435 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); C07K 7/08 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
A61K 48/00 (2013.01); A61K 9/0048 (2013.01); A61K 38/10 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C07K 14/4703 (2013.01); C07K 16/00 (2013.01); C12N 15/11 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 38/16 (2013.01); A61N 5/10 (2013.01); C07K 2319/02 (2013.01); C07K 2319/10 (2013.01);
Abstract
Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).